Navigation Links
Low Acid Coffee Backed By Scientific Research
Date:3/27/2008

WOODLAND, Calif., March 27 /PRNewswire/ -- Puroast(R) Low Acid Coffee has conducted both chemistry and consumer research to confirm its claims that its great tasting, gourmet coffee provides symptom relief for those with stomach problems caused by their morning brew. Puroast(R) achieves this without extractions, substitutes or additives; it uses a natural process that helps ensure the full-bodied taste.

Prior chemistry research at University of California, Davis found Puroast(R) to have less than half the acid of all other commercial coffees. The company now announces first stage results of consumer research that shows nearly 90% of those tested experienced symptom relief when drinking Puroast(R) Low Acid Coffee.

"This is important research for both our company and the consumer," observed Kerry Sachs, co-founder of Puroast(R) Low-Acid Coffee. "When you combine these scientific studies with market data that indicates there are several million consumers who have stomach discomfort from coffee drinking, it's clear Puroast(R) has explosive market potential and delivers a strong consumer benefit."

Arthur R. Euler, MD, a gastroenterologist who directed Glaxo's Zantac(R) Clinical Development Unit, conducted a survey of 250 consumers who came to Puroast(R)'s website looking for a solution to their coffee-related gastrointestinal symptoms. Zantac(R) is a drug used to treat upper gastrointestinal symptoms and is often prescribed by primary care doctors. This research's objective was to evaluate Puroast(R) Low Acid Coffee's effect on these stomach symptoms.

"Our study asked consumers to brew and drink Puroast(R), then compare the symptoms that developed, if any, versus symptoms that developed when they drank other brands of coffee," states Dr. Euler. The survey also asked the participant to evaluate Puroast(R)'s taste. "88% of respondents stated Puroast(R) provided relief of their gut symptoms caused by coffee, and 95% said they would purchas
'/>"/>

SOURCE Puroast
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Thermo Fisher Scientific Introduces Breakthrough in RNA-Interference Technology
2. Industry Executives Finding Value in Shift of Scientific Publications
3. Childrens Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD
4. Molecular Biometrics Hires Denny Sakkas, PhD Renowned Yale Embryologist and International Thought-Leader, as Chief Scientific Officer; Opening U.S. Research Facility
5. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
6. Second Thoughts about Fluoride, Reports Scientific American
7. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
8. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
9. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
10. New Risk Factor for Heart Disease Identified in Very Young Children, According to Study at American Heart Association Scientific Sessions
11. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014   Regulus Therapeutics Inc ... leading the discovery and development of innovative medicines targeting ... Ph.D., President and CEO of Regulus, will present a ... Jaffray Healthcare Conference at the New York Palace Hotel ... The presentation will be webcast at the time of ...
(Date:11/26/2014)... , Inc. (NASDAQ: BIOS ) announced today that ... at the Bank of America Merrill Lynch 2014 Leveraged Finance Conference ... , Wednesday, December 3, 2014 , , , , Time: ... Location: , , , Boca Raton Resort and Club, Florida , ... BioScrip, Inc. is a leading national provider of infusion and ...
(Date:11/26/2014)... , Nov. 26, 2014 The medical ... a rate of 4%, with world market revenues ... Information. MRI and other types of medical imaging ... treatment of numerous medical conditions in children and ... techniques. Kalorama,s report, Medical Imaging Markets , ...
Breaking Medicine Technology:Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3
... Novelos Therapeutics, Inc. (OTCQX: NVLT) , a pharmaceutical ... of cancer, today announced that the University of ... institution, has successfully completed the first cohort in ... trial of I-124-CLR1404 (LIGHT), a cancer-targeted PET imaging ...
... 2012 HIGHLIGHTS :2012 Results (all ... Q1 2012 reported sales increased 5% to $665 million, a new ... Fine Chemicals ("SAFC") organic sales growth of 4% and 1%, respectively.  ... exchange rates reduced otherwise reportable sales by 2%. , ...
Cached Medicine Technology:Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center 2Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center 3Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center 4Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center 5Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 2Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 3Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 4Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 5Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 6Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 7Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 8Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 9Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 10Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 11Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 12Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 13
(Date:11/28/2014)... Dr. Diane Walder, one of South ... to her practice called Ultrashape that is designed to help ... in just six weeks. Ultrashape has been praised by patients ... results when compared to other types of external fat reduction. ... said Dr. Walder. , According to Dr. Walder, Ultrashape ...
(Date:11/28/2014)... Texas (PRWEB) November 28, 2014 Dr. Paul Vitenas, ... will hold a Glitter & Glow Holiday Event for those in ... treatments offered at his practice. Glitter & Glow will take place ... Dr. Vitenas’ new location in the heart of Houston at 4208 ... of holidays and hope that you will come and celebrate the ...
(Date:11/28/2014)... Secura Consultants, based in Minneapolis, ... organizations in the country focused on delivering exemplary ... Secura Consultants is proud to offer complimentary Buy-Sell ... a leading global financial company. , Many businesses ... ownership interest comes the need for business succession ...
(Date:11/28/2014)... News) -- Celebration can quickly turn to tragedy ... experts say. Over the last decade, more than ... people were using turkey fryers, according to the U.S. ... for a patient who tried to deep fry the ... any circumstances," Dr. Arthur Sanford, a burn surgeon at ...
(Date:11/28/2014)... Alex Kramer HealthDay Reporter ... involved in the kitchen, through cooking classes or at home, ... to a recent review. Cooking programs and classes for ... according to the new research. And, although the review didn,t ... that such programs might help children develop long-lasting healthy habits. ...
Breaking Medicine News(10 mins):Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 3Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3Health News:Secura Consultants Offers Complimentary Buy-Sell Agreement Reviews 2Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2Health News:Want Kids to Eat Better? Get Them Cooking 2Health News:Want Kids to Eat Better? Get Them Cooking 3
... to determine how gender affects body,s reaction to HIV , ... may explain why HIV infection progresses faster to AIDS in ... say. , Their study found that a receptor molecule involved ... in women than in men. This then leads to differences ...
... , , , ... of St. Jude Children,s Research Hospital, has been invited to give ... , , The Leeuwenhoek Lecture, named ... the field of microbiology. Webster will present the lecture next summer. ...
... AURORA, Ohio, July 13 Arizona Cardinals 2008 NFC ... word to parents that vision problems can interfere with a child,s ... been told your child has perfect vision or 20/20 vision, your ... problem," warns Fitzgerald. , , Do ...
... tolerance to sudden hurts, , MONDAY, July 13 (HealthDay News) ... toe or experiencing some other painful incident? , Your ... , In a study that suggests bad words aren,t all ... hand in ice-cold water were able to withstand the frigid ...
... found that postmenopausal women who have taken a combined ... risk of developing progestin-accelerated breast tumors. Now, University of ... spice derived from the turmeric root, could reduce the ... therapy. "Approximately 6 million women in the United ...
... , , PARAMUS, N.J., July 13 Smart Balance, ... at www.smartbalance.com on August 6, 2009, at 9:30 ... at approximately 8:30 a.m. EDT the same day. The webcast will ... Investors and analysts may participate via conference call by dialing 1-800-895-0198 ...
Cached Medicine News:Health News:Immune Response May Speed AIDS Progression in Women 2Health News:St. Jude Virologist Honored by the Royal Society 2Health News:Larry Fitzgerald Offers Advice for Parents With Struggling Readers 2Health News:Larry Fitzgerald Offers Advice for Parents With Struggling Readers 3Health News:Larry Fitzgerald Offers Advice for Parents With Struggling Readers 4Health News:A Curse or Two Might Quell the Pain 2Health News:A Curse or Two Might Quell the Pain 3Health News:Asian spice could reduce breast cancer risk in women exposed to hormone replacement therapy 2
Anterior Stromal Puncture Cannula, 25 g. For treatment of recurrent corneal erosion. Overall length 24 mm. 5/box....
Viscoelastic Cannula, 23 g. Angled. 7 mm angled tip cannula with unique hub that facilitates flow of viscoelastic material. Overall length 23 mm. 5/box....
Anterior Chamber Needle, 21 g., 8 mm from bend to tip. Overall length 25 mm. 5/box....
Anterior Chamber Needle, 25 g. Angled. 9 mm angled tip. Overall length 19 mm. 5/box....
Medicine Products: